Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free NBIX Stock Alerts
Live Earnings Conference Call: Neurocrine Biosciences' Q1 2026 earnings call is happening now. Follow this link to listen to the live Q1 2026 earnings call for Neurocrine Biosciences. Listen live.

Neurocrine Biosciences (NBIX) Competitors

Neurocrine Biosciences logo
$135.06 +0.99 (+0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$143.76 +8.70 (+6.44%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NBIX vs. ALNY, BIIB, UTHR, INCY, and IONS

Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.

How does Neurocrine Biosciences compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Neurocrine Biosciences has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$4.29B9.37$313.75M$3.6682.27
Neurocrine Biosciences$2.86B4.75$478.60M$4.6628.98

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 29 mentions for Alnylam Pharmaceuticals and 17 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.87 beat Alnylam Pharmaceuticals' score of 0.64 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
9 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive
Neurocrine Biosciences
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neurocrine Biosciences has a net margin of 16.73% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Neurocrine Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals11.72% 85.76% 10.32%
Neurocrine Biosciences 16.73%16.48%11.49%

Alnylam Pharmaceuticals currently has a consensus target price of $471.96, indicating a potential upside of 56.74%. Neurocrine Biosciences has a consensus target price of $180.45, indicating a potential upside of 33.61%. Given Alnylam Pharmaceuticals' higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.77
Neurocrine Biosciences
0 Sell rating(s)
5 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.82

Summary

Alnylam Pharmaceuticals and Neurocrine Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Biogen?

Biogen (NASDAQ:BIIB) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

In the previous week, Biogen had 33 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 50 mentions for Biogen and 17 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.87 beat Biogen's score of 0.81 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
21 Very Positive mention(s)
7 Positive mention(s)
14 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurocrine Biosciences
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.94B2.81$1.29B$9.3220.29
Neurocrine Biosciences$2.86B4.75$478.60M$4.6628.98

Neurocrine Biosciences has a net margin of 16.73% compared to Biogen's net margin of 13.81%. Neurocrine Biosciences' return on equity of 16.48% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen13.81% 12.83% 8.01%
Neurocrine Biosciences 16.73%16.48%11.49%

Biogen currently has a consensus target price of $214.23, indicating a potential upside of 13.27%. Neurocrine Biosciences has a consensus target price of $180.45, indicating a potential upside of 33.61%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
13 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.50
Neurocrine Biosciences
0 Sell rating(s)
5 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.82

Biogen has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

87.9% of Biogen shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Biogen on 12 of the 16 factors compared between the two stocks.

How does Neurocrine Biosciences compare to United Therapeutics?

Neurocrine Biosciences (NASDAQ:NBIX) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

United Therapeutics has a net margin of 41.94% compared to Neurocrine Biosciences' net margin of 16.73%. United Therapeutics' return on equity of 19.30% beat Neurocrine Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Neurocrine Biosciences16.73% 16.48% 11.49%
United Therapeutics 41.94%19.30%17.29%

In the previous week, United Therapeutics had 2 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 19 mentions for United Therapeutics and 17 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.87 beat United Therapeutics' score of 0.75 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurocrine Biosciences
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
United Therapeutics
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurocrine Biosciences presently has a consensus target price of $180.45, suggesting a potential upside of 33.61%. United Therapeutics has a consensus target price of $601.50, suggesting a potential upside of 5.12%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences
0 Sell rating(s)
5 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.82
United Therapeutics
0 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.77

Neurocrine Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 10.3% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$2.86B4.75$478.60M$4.6628.98
United Therapeutics$3.18B7.88$1.33B$27.9020.51

Summary

United Therapeutics beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Incyte?

Incyte (NASDAQ:INCY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Incyte has a net margin of 26.71% compared to Neurocrine Biosciences' net margin of 16.73%. Incyte's return on equity of 26.66% beat Neurocrine Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Incyte26.71% 26.66% 19.77%
Neurocrine Biosciences 16.73%16.48%11.49%

In the previous week, Incyte had 17 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 34 mentions for Incyte and 17 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.87 beat Incyte's score of 0.60 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Incyte
11 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurocrine Biosciences
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Incyte presently has a consensus target price of $104.26, suggesting a potential upside of 6.97%. Neurocrine Biosciences has a consensus target price of $180.45, suggesting a potential upside of 33.61%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte
1 Sell rating(s)
10 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.43
Neurocrine Biosciences
0 Sell rating(s)
5 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.82

Incyte has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

97.0% of Incyte shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 17.8% of Incyte shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Incyte has higher revenue and earnings than Neurocrine Biosciences. Incyte is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$5.36B3.63$1.29B$7.0813.77
Neurocrine Biosciences$2.86B4.75$478.60M$4.6628.98

Summary

Incyte beats Neurocrine Biosciences on 10 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Neurocrine Biosciences has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$944M13.17-$381.39M-$2.07N/A
Neurocrine Biosciences$2.86B4.75$478.60M$4.6628.98

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neurocrine Biosciences has a net margin of 16.73% compared to Ionis Pharmaceuticals' net margin of -30.91%. Neurocrine Biosciences' return on equity of 16.48% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-30.91% -58.65% -10.07%
Neurocrine Biosciences 16.73%16.48%11.49%

In the previous week, Ionis Pharmaceuticals had 16 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 33 mentions for Ionis Pharmaceuticals and 17 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.87 beat Ionis Pharmaceuticals' score of 0.54 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurocrine Biosciences
7 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ionis Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

Ionis Pharmaceuticals presently has a consensus target price of $99.35, suggesting a potential upside of 32.03%. Neurocrine Biosciences has a consensus target price of $180.45, suggesting a potential upside of 33.61%. Given Neurocrine Biosciences' higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Ionis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.86
Neurocrine Biosciences
0 Sell rating(s)
5 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.82

Summary

Neurocrine Biosciences beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBIX vs. The Competition

Export
MetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$13.58B$3.10B$6.25B$11.87B
Dividend YieldN/A1.91%2.73%5.21%
P/E Ratio28.9818.3729.0328.47
Price / Sales4.75281.03476.1060.92
Price / Cash26.2950.4327.6236.52
Price / Book4.144.339.676.67
Net Income$478.60M$72.19M$3.55B$332.53M
7 Day Performance5.56%2.02%1.75%2.03%
1 Month Performance2.63%6.41%5.66%9.23%
1 Year Performance23.06%37.69%34.42%39.62%

Neurocrine Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBIX
Neurocrine Biosciences
4.3649 of 5 stars		$135.06
+0.7%		$180.45
+33.6%		N/A$13.58B$2.86B28.982,000
ALNY
Alnylam Pharmaceuticals
4.3503 of 5 stars		$308.51
+1.0%		$472.78
+53.2%		N/A$40.77B$3.71B180.422,770
BIIB
Biogen
3.8003 of 5 stars		$180.67
-2.0%		$211.81
+17.2%		N/A$27.06B$9.89B20.517,500
UTHR
United Therapeutics
3.5186 of 5 stars		$566.99
0.0%		$601.50
+6.1%		N/A$24.86B$3.18B20.321,400
INCY
Incyte
4.0887 of 5 stars		$95.71
+1.1%		$104.89
+9.6%		N/A$18.84B$5.14B14.932,844

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NBIX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel